BioSpace News Archive

Aro Biotherapeutics today announced the appointment of Mittie Doyle, MD, FACR as Chief Medical Officer and a member of the company’s executive leadership team.

Axonics ® to Report Third Quarter 2021 Financial Results on November 4

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022.

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 LATTICE-UC study evaluating deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor

Rocket Pharmaceuticals, Inc. today announces that Gaurav Shah, M.D., chief executive officer, will deliver an in-person company presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference virtually and in Carlsbad, CA.

Initial eight patients treated in ongoing first-in-human, open-label, dose-finding trial of CBP/p300 inhibitor in late-line mCRPC patients

Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to expand to additional candidates

DTx Pharma, Inc. today announced that Dr. Arthur Suckow, Co-Founder and CEO, and Denise Bevers, COO, will participate in the 8th Annual Virtual Solebury Trout Fall Private Company Showcase 2021 co-hosted with BMO on October 14, 2021.

Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares at a public offering price of $2.50 per share and accompanying warrant.

The increasing adoption of latest technology for medical therapeutic applications worldwide will help boost the growth of the global smart hospitals market during the forecast period, 2020 to 2030.